Healthcare Industry News: Merck
News Release - December 7, 2017
Dr. Aradhana Ghosh Joins Precision Medicine Leader Syapse As Vice President of OncologyOncologist-Executive Brings Extensive Medical and Informatics Experience to Rapidly Growing Precision Medicine Company
SAN FRANCISCO, Dec. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Syapse, a market leader in precision medicine solutions, announced today that Dr. Aradhana Ghosh has joined the company as Vice President of Oncology. An expert in specialty care and oncology, Dr. Ghosh will use her deep experience in clinical practice, healthcare technology, and hospital administration to help Syapse bring precision medicine to more healthcare providers and improve patient care.
"Precision medicine presents the most significant opportunity to improve care for cancer patients today," said Dr. Ghosh. "When I was practicing in a large health system, I wished that I had access to the precision medicine that Syapse enables. The team is taking a unique approach to breaking down barriers that will make precision medicine available to more patients, and I'm excited to help with this mission."
In her role as Vice President of Oncology, Dr. Ghosh will provide clinical expertise to product development, corporate strategy, and sales implementation as she leads the Syapse clinical group.
Dr. Ghosh is a board-certified medical oncologist who has practiced hematology-oncology at Kaiser Permanente, where she also served on the Clinical Trials Steering Committee and served as a physician champion for the enterprise electronic health record (EHR) rollout. Dr. Ghosh went on to become Medical Director of Specialty Care for Santa Clara Health & Hospital System, where she led efforts to improve access to care through clinical quality initiatives and physician alignment. Prior to that, Dr. Ghosh served as a Physician Executive at McKesson, focusing on medical informatics, and most recently as a Medical Oncologist at IBM Watson Health.
"Aradhana is a tremendous addition to the Syapse team," said Syapse CEO Ken Tarkoff. "Her vast experience at the intersection of clinical medicine and technology will help Syapse continue our rapid growth, and I know our health system partners will find Aradhana to be an especially valuable resource as they deliver precision medicine to more patients."
Dr. Ghosh joins Syapse at a time when many health systems are implementing precision medicine programs to provide cancer patients with the best treatments available. Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives, Dignity Health, and others have partnered with Syapse to deliver personalized care that matches patients with targeted, cutting-edge treatments based on their individual genomic makeup, an approach that has been shown to improve care, lower costs, and increase efficiency.
Technology is crucial to implementing precision medicine, as demonstrated by a recent survey of oncology leaders, and Dr. Ghosh has deep expertise helping healthcare providers implement innovative technology.
Dr. Ghosh received her medical degree from Albany Medical College in 2000 and completed her residency training in internal medicine at Temple University Hospital in 2003. She went on to complete her subspecialty training in hematology and oncology at New York Hospital – Cornell in 2006.
Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Our software platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. By bringing together leading healthcare innovators into a unified ecosystem, we are working toward a future in which all cancer patients have access to the best personalized care, regardless of location or income. Our customers—including Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives and Dignity Health—manage one million active cancer cases at nearly 300 hospitals in 25 states. Headquartered in San Francisco, Syapse is backed by investors including Social Capital, Safeguard Scientifics, Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Merck Global Health Innovation Fund, Medidata Solutions, Roche Venture Fund, and Amgen Ventures.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.